BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 36499394)

  • 1. The Interplay of Lung Cancer, COVID-19, and Vaccines.
    Trivanović D; Peršurić Ž; Agaj A; Jakopović M; Samaržija M; Bitar L; Pavelić K
    Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety.
    Fendler A; de Vries EGE; GeurtsvanKessel CH; Haanen JB; Wörmann B; Turajlic S; von Lilienfeld-Toal M
    Nat Rev Clin Oncol; 2022 Jun; 19(6):385-401. PubMed ID: 35277694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COVID-19 vaccines: Knowing the unknown.
    Lv H; Wu NC; Mok CKP
    Eur J Immunol; 2020 Jul; 50(7):939-943. PubMed ID: 32437587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARS-CoV-2 infection and COVID-19 vaccination in cancer patients undergoing immune checkpoint inhibitors.
    Yang Y; Xu G
    Cell Death Dis; 2023 Jun; 14(6):390. PubMed ID: 37391394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies.
    Frederiksen LSF; Zhang Y; Foged C; Thakur A
    Front Immunol; 2020; 11():1817. PubMed ID: 32793245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2-related and Covid-19 vaccine-induced thromboembolic events: A comparative review.
    Afshar ZM; Barary M; Babazadeh A; Hosseinzadeh R; Alijanpour A; Miri SR; Sio TT; Sullman MJM; Carson-Chahhoud K; Langer F; Ebrahimpour S
    Rev Med Virol; 2022 Jul; 32(4):e2327. PubMed ID: 35112763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progress and Challenges in the Development of COVID-19 Vaccines and Current Understanding of SARS-CoV-2- Specific Immune Responses.
    Kim KD; Hwang I; Ku KB; Lee S; Kim SJ; Kim C
    J Microbiol Biotechnol; 2020 Aug; 30(8):1109-1115. PubMed ID: 32627758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [COVID-19 vaccine safety].
    Chaparro Mérida NA; Moreno Samper D; Lacato AOF
    Rev Peru Med Exp Salud Publica; 2021; 38(4):634-642. PubMed ID: 35385018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [SARS-CoV-2 vaccines].
    Benfield TL; Helweg-Larsen J
    Ugeskr Laeger; 2021 Mar; 183(10):. PubMed ID: 33734065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of the safety and efficacy of current COVID-19 vaccines.
    Huang Z; Su Y; Zhang T; Xia N
    Front Med; 2022 Feb; 16(1):39-55. PubMed ID: 35122210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lung Cancer and Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Identifying Important Knowledge Gaps for Investigation.
    Rolfo C; Meshulami N; Russo A; Krammer F; García-Sastre A; Mack PC; Gomez JE; Bhardwaj N; Benyounes A; Sirera R; Moore A; Rohs N; Henschke CI; Yankelevitz D; King J; Shyr Y; Bunn PA; Minna JD; Hirsch FR
    J Thorac Oncol; 2022 Feb; 17(2):214-227. PubMed ID: 34774792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination.
    Zheng C; Kar I; Chen CK; Sau C; Woodson S; Serra A; Abboud H
    CNS Drugs; 2020 Sep; 34(9):879-896. PubMed ID: 32780300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serological findings following the second and third SARS-CoV-2 vaccines in lung transplant recipients.
    Bárczi E; Varga V; Nagy A; Eszes N; Jáky-Kováts Z; Müller V; Bohács A
    Immun Inflamm Dis; 2022 Aug; 10(8):e646. PubMed ID: 35894705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurological and neuropsychological adverse effects of SARS-CoV-2 vaccines - where do we stand?
    Aliasin MM; Yazdanpanah N; Rezaei N
    Rev Neurosci; 2022 Oct; 33(7):721-743. PubMed ID: 35334195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.
    Lambert PH; Ambrosino DM; Andersen SR; Baric RS; Black SB; Chen RT; Dekker CL; Didierlaurent AM; Graham BS; Martin SD; Molrine DC; Perlman S; Picard-Fraser PA; Pollard AJ; Qin C; Subbarao K; Cramer JP
    Vaccine; 2020 Jun; 38(31):4783-4791. PubMed ID: 32507409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COVID-19 vaccination in cancer patients: a narrative review.
    Seneviratne SL; Yasawardene P; Wijerathne W; Somawardana B
    J Int Med Res; 2022 Mar; 50(3):3000605221086155. PubMed ID: 35313761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2 will constantly sweep its tracks: a vaccine containing CpG motifs in 'lasso' for the multi-faced virus.
    Oberemok VV; Laikova KV; Yurchenko KA; Marochkin NA; Fomochkina II; Kubyshkin AV
    Inflamm Res; 2020 Sep; 69(9):801-812. PubMed ID: 32656668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COVID-19 immunization in people with cancer-Is it safe and efficient? What do we know?
    Lazăr DE; Munteanu A
    Tumori; 2022 Oct; 108(5):420-430. PubMed ID: 35426773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SARS-CoV-2: previous coronaviruses, immune response, and development of vaccines.
    De León-Rodríguez SG; Hernández-Rico B; Olmo-Vázquez GD; Cruz-Dávalos I; Bonifaz LC
    Bol Med Hosp Infant Mex; 2020; 77(5):252-261. PubMed ID: 33064679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.